Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02290509 · ClinicalTrials.gov registry record · Phase 3
Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age
A Phase 3 study of Influenza, sponsored by Protein Sciences Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,350
- Enrollment target
- 10
- Study locations
NCT02290509 is a Phase 3 study of Influenza that has completed, run by Protein Sciences Corporation. The registered enrollment target is 1,350 participants, below the 36,795-participant average among 156 other Influenza trials with a reported enrollment target (96% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT02290509, a Phase 3 study of Influenza, has completed, sponsored by Protein Sciences Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,350 participants
- Enrollment target
- 10
- Study locations
Study Summary
Randomized, double-blind trial of safety and immunogenicity of Flublok Quadrivalent versus Inactivated Influenza Vaccine (IIV4) in 1350 healthy, medically stable adults 18-49 years of age. Serum samples for Hemagglutinin Inhibition titers will be determined pre- and 28 days post-vaccination. Subjects will be followed for 6 months after vaccination for serious and/or medically-attended adverse events.
Conditions Studied
Interventions
- BIOLOGICAL Flublok Quadrivalent
- BIOLOGICAL Inactivated Influenza Vaccine (IIV4)
Study Locations (10)
Nebraska
- Meridian Research - Bellevue
- Meridian Clinical Research - Omaha
Texas
- Benchmark Reseach - Austin
- Benchmark Research - Fort Worth - Fort Worth
California
- Benchmark Research - Sacramento - Sacramento
Florida
- Clinical Research of South Florida - Coral Gables
Georgia
- Meridian Clinical Research - Savannah
Kansas
- Heartland Research Associates, LLC - Wichita
Louisiana
- Benchmark Research - Metairie
South Dakota
- Meridian Research - Dakota Dunes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,350 participants |
| Start Date | 2014-10 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02290509
The ClinicalTrials.gov registry entry for NCT02290509 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,350 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,795-participant average among 156 other Influenza trials with a reported enrollment target (96% lower). The listed sponsor is Protein Sciences Corporation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which Flublok Quadrivalent is the first listed.
NCT02290509 reports 10 study locations spanning 8 distinct geographic areas - top geographies include Nebraska, Texas, California.
Frequently Asked Questions
What is clinical trial NCT02290509 about?
NCT02290509 is a clinical study titled "Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age". Randomized, double-blind trial of safety and immunogenicity of Flublok Quadrivalent versus Inactivated Influenza Vaccine (IIV4) in 1350 healthy, medically stable adults 18-49 years of age. Serum samples for Hemagglutinin Inhibition titers will be determined pre- and 28 days post-vaccination. Subject...
What is the current status of trial NCT02290509?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,350 participants. The study started on 2014-10. Estimated completion is 2015-05.
What conditions does trial NCT02290509 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT02290509?
The interventions under investigation include: Flublok Quadrivalent (BIOLOGICAL), Inactivated Influenza Vaccine (IIV4) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02290509?
This trial is sponsored by Protein Sciences Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02290509 being conducted?
This trial has 10 study locations across California, Florida, Georgia, Kansas, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
RECRUITING · Phase 3
-
A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza
ACTIVE NOT RECRUITING · Phase 3
-
Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years
COMPLETED · Phase 3
-
Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age
COMPLETED · Phase 3
-
Study of Quadrivalent Influenza Vaccine Among Children
COMPLETED · Phase 3
-
Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.